J Cancer Res Clin Oncol. 2018 Sep 28. doi: 10.1007/s00432-018-2758-6. [Epub ahead of print]
Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X1,2,3, Gu YK1,2,3, Li SL1,2,3, Chen H1,2,4, Chen MS1,2,5, Cai QQ1,2,6, Deng HX1,2,3, Zuo MX7,8,9, Huang JH10,11,12.
Author information
1
State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's Republic of China.
2
Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China.
3
Department of Minimally Invasive Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China.
4
Department of Clinical Laboratory, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China.
5
Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China.
6
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China.
7
State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's Republic of China. [email protected].
8
Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China. [email protected].
9
Department of Minimally Invasive Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China. [email protected].
10
State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's Republic of China. [email protected].
11
Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People's Republic of China. [email protected].
12
Department of Minimally Invasive Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China. [email protected].
Abstract
PURPOSE:
Anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) therapy has shown promise in tumor immunotherapy. Our objectives were to measure pre-treatment serum-soluble PD-L1 (sPD-L1) levels and to assess the relationships between sPD-L1 levels and clinical characteristics, prognosis, and tumor tissue PD-L1 expression in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).
METHODS:
Pre-treatment serum sPD-L1 levels were measured with an enzyme-linked immunosorbent assay (ELISA) in 81 patients with HBV-related HCC and compared to those in 49 healthy controls. The association between serum sPD-L1 levels and prognosis was assessed using survival analysis. The correlation between paired serum sPD-L1 levels and tumor PD-L1 expression (in resected tissue homogenates) was assessed in a separate group of 20 patients with HBV-related HCC.
RESULTS:
Median sPD-L1 concentration in patients with HBV-related HCC was 5.129 (range 0.140-12.391) ng/mL and in healthy controls was 0.836 (range 0.105-2.168) ng/mL (p < 0.001). On multivariate analysis, sPD-L1 levels were significant independent predictors of disease-free survival (hazard ratio [HR] 3.503; 95% confidence interval [CI], 1.559-7.871; p = 0.002) and overall survival (HR 3.399; 95% CI 1.308-8.831; p = 0.012). Positive correlation (r = 0.527, p = 0.017) between serum sPD-L1 and tumor PD-L1 expression was observed. Tumor expression of PD-L1 was significantly higher in those with serum sPD-L1 concentrations above vs. below the median level of 5.471 ng/ml (p = 0.012).
CONCLUSIONS:
In patients with HBV-related HCC, serum sPD-L1 concentrations were elevated, and positively correlated with tumor PD-L1 expression. Lower pre-treatment serum sPD-L1 levels were predictors of more favorable disease-free and overall survival. Serum sPD-L1 testing has a potential role in HBV-related HCC disease assessment, systemic therapy choices and survival prediction.
KEYWORDS:
HBV-related hepatocellular carcinoma; Hepatitis B virus; PD-L1; Prognosis; Soluble PD-L1
PMID:
30267213
DOI:
10.1007/s00432-018-2758-6
作者: StephenW 时间: 2018-10-1 13:38
J Cancer Res Clin Oncol。 2018年9月28日doi：10.1007 / s00432-018-2758-6。 [提前打印]
可溶性程序性细胞死亡 - 配体1的治疗前血清水平预测乙型肝炎相关肝细胞癌患者的预后。
汉X1,2,3，顾YK1,2,3，李SL1,2,3，陈H1,2,4，陈MS1,2,5，蔡QQ1,2,6，邓HX1,2,3，左MX7,8,9，黄JH10,11,12。
作者信息